DOCSLIB.ORG

Laakeluettelo-Liite 1

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Laakeluettelo-Liite 1 LÄÄKELUETTELON AINEET, LIITE 1. 1 ÄMNENA I LÄKEMEDELSFOÖRTECKNINGEN, BILAGA 1. Suomenkielinen nimi, Latinankielinen nimi, Ruotsinkielinen nimi, Englanninkielinen nimi, Finskt namn Latinskt namn Svenskt namn Engelskt namn (N)-Hydroksietyyli- (N)-Hydroxy- (N)-Hydroxietyl- (N)-Hydroxyethyl- prometatsiini aethylprometazinum prometazin promethazine 2,4-Diklooribentsyyli-alkoholi 2,4-Dichlorbenzyl- 2,4-Diklorbensylalkohol 2,4-Dichlorobenzyl alcohol alcoholum 2-Isopropoksifenyyli-N- 2-Isopropoxyphenyl-N- 2-Isopropoxifenyl-N- 2-Isopropoxyphenyl-N- metyylikarbamaatti methylcarbamas metylkarbamat methylcarbamate 4-Dimetyyliaminofenoli 4-Dimethyl- 4-Dimetylaminofenol 4-Dimethylaminophenol aminophenolum 6,7-diF-1-MeTIQ 6,7-diF-1-MeTIQ 6,7-diF-1-MeTIQ 6,7-diF-1-MeTIQ Abakaviiri Abacavirum Abakavir Abacavir Abareliksi Abarelixum Abarelix Abarelix Abatasepti Abataceptum Abatacept Abatacept Abirateroni Abirateronum Abirateron Abiraterone Absiksimabi Abciximabum Absiximab Abciximab Adalimumabi Adalimumabum Adalimumab Adalimumab Adapaleeni Adapalenum Adapalen Adapalene Adefoviiridipivoksiili Adefovirum dipivoxilum Adefovirdipivoxil Adefovir dipivoxil Ademetioniini Ademetioninum Ademetionin Ademetionine Adenosiini Adenosinum Adenocin Adenosine Adinatsolaamimesilaatti Adinazolami mesilas Adinazolammesilat Adinazolam mesilate Adipiodoni Adipiodonum Adipiodon Adipiodone Adrafiniili Adrafinilum Adrafinil Adrafinil Adrenaliini Adrenalinum Adrenalin Adrenaline Adrenaliinitartraatti Adrenalini tartras Adrenalintartrat Adrenaline tartrate Adrenaloni Adrenalonum Adrenalon Adrenalone Afamelanotidi Afamelanotidum Afamelanotid Afamelanotide Afatinibi Afatinibum Afatinib Afatinib Aflibersepti Afliberceptum Aflibercept Aflibercept Afobatsoli Afobazolum Afobazol Afobazole Afoksolaneeri Afoxolanerum Afoxolaner Afoxolaner Agalsidaasi Agalsidasum Agalsidas Agalsidase Aglepristoni Aglepristonum Aglepriston Aglepristone Agomelatiini Agomelatinum Agomelatin Agomelatine Aimaliini Ajmalinum Ajmalin Ajmaline Akamprosaatti Acamprosatum Acamprosat Acamprosate Akarboosi Acarbosum Akarbos Acarbose Aklarubisiini Aclarubicinum Aklarubicin Aclarubicin Aklidinium Aclidinium Aclidinium Aclidinium Akrivastiini Acrivastinum Acrivastin Acrivastine Aksikabtageenisiloleuseeli Axicabtagenum Axikabtagenciloleucel Axicabtagene ciloleucel Aksitinibi Axitinibum Axitinib Axitinib Alaproklaatti Alaproclatum Alaproklat Alaproclate Alatrofloksasiini Alatrofloxacinum Alatrofloxacin Alatrofloxacin Albendatsoli Albendazolum Albendazol Albendazole Albiglutidi Albiglutidum Albiglutid Albiglutide Albumiini, ihmisen Albuminum humanum Albumin Albumin, human Albumiinitannaatti Albumini tannas Albumintannat Albumin tannate Aldesleukiini Aldesleukinum Aldesleukin Aldesleukin Päätös 19.3.2019 LÄÄKELUETTELON AINEET, LIITE 1. 2 ÄMNENA I LÄKEMEDELSFOÖRTECKNINGEN, BILAGA 1. Aldesulfoninatrium Aldesulfonum natricum Aldesulfonnatrium Aldesulfone sodium Aldosteroni Aldosteronum Aldosteron Aldosterone Alektinibi Alectinibum Alektinib Alectinib Alemtutsumabi Alemtuzumabum Alemtuzumab Alemtuzumab Alendronihappo Acidum alendronicum Alendronsyra Alendronic acid Alfakalsidoli Alfacalcidolum Alfakalcidol Alfacalcidol Alfaksaloni Alfaxalonum Alfaxalon Alfaxalone; alphaxalone Alfentaniili Alfentanilum Alfentanil Alfentanil Alfutsosiini Alfuzosinum Alfuzosin Alfuzosin Algeldraatti Algeldratum Algeldrat Algeldrate Algiinihappo Acidum alginicum Alginsyra Alginic acid Alglukosidaasialfa Alglucosidase alfa Alglukosidas alfa Alglucosidase alfa Alimematsiini Alimemazinum Alimemazin Alimemazine Aliskireenifumaraatti Aliskireni fumaras Aliskirenfumarat Aliskiren fumarate Alitretinoiini Alitretinoinum Alitretinoin Alitretinoin Alklofenaakki Alclofenacum Alklofenak Alclofenac Alklometasonidipropionaatti Alclometasoni dipropionas Alklometason-dipropionat Alclometasone dipropionate Alkuroniumkloridi Alcuronii chloridum Alkuroniumklorid Alcuronium chloride Allobarbitaali Allobarbitalum Allobarbital Allobarbital Allopurinoli Allopurinolum Allopurinol Allopurinol Allyyliestrenoli Allylestrenolum Allylestrenol Allylestrenol Almitriini Almitrinum Almitrin Almitrine Almotriptaani Almotriptanium Almotriptan Almotriptan Alogliptiini Alogliptinum Alogliptin Alogliptin Aloksipriini Aloxiprinum Aloxiprin Aloxiprin Alpratsolaami Alprazolamum Alprazolam Alprazolam Alprenololi Alprenololum Alprenolol Alprenolol Alprostadiili Alprostadilum Alprostadil Alprostadil Alteplaasi Alteplasum Alteplas Alteplase Altrenogesti Altrenogestum Altrenogest Altrenogest Altretamiini Altretaminum Altretamin Altretamine Aluminiumasetotartraatti Aluminii acetotartras Aluminiumacetotartrat Aluminium acetotartrate Aluminiumklofibraatti Aluminii clofibras Aluminiumklofibrat Aluminium clofibrate Alveriini Alverinum Alverin Alverine Amantadiini Amantadinum Amantadin Amantadine Ambatsoni Ambazonum Ambazon Ambazone Ambenonium Ambenonium Ambenonium Ambenonium Ambenoniumkloridi Ambenonii chloridum Ambenoniumklorid Ambenonium chloride Ambrisentaani Ambrisentanum Ambrisentan Ambrisentan Ambroksoli Ambroxolum Ambroxol Ambroxol Ambroksolihydrokloridi Ambroxoli Ambroxolhydroklorid Ambroxol hydrochloride Ambutoniumbromidi Ambutonii bromidum Ambutoniumbromid Ambutonium bromide Ametsiniummetilsulfaatti Amezinii metilsulfas Ameziniummetilsulfat Amezinium metilsulfate Amfepramoni Amfepramonum Amfepramon Amfepramone Amfetamiini Amphetaminum Amfetamin Amphetamine; amfetamine Amfetaminiili Amfetaminilum Amfetaminil Amfetaminil Amfoterisiini Amphotericinum Amfotericin Amphotericin Amifampridiini Amifampridinum Amifampridin Amifampridine Amifostiini Amifostinum Amifostin Amifostine Amikasiini Amikacinum Amikacin Amikacin Päätös 19.3.2019 LÄÄKELUETTELON AINEET, LIITE 1. 3 ÄMNENA I LÄKEMEDELSFOÖRTECKNINGEN, BILAGA 1. Amiloridi Amiloridum Amilorid Amiloride Aminoakridiini Aminoacridinum Aminoakridin Aminoacridine Aminoetikkahappo (glysiini) Acidum aminoaceticum Aminoättiksyra (glycin) Aminoacetic acid Aminofenatsoni Aminophenazonum Aminofenazon Aminophenazone Aminofylliini Aminophyllinum Aminofyllin Aminophylline Aminoglutetimidi Aminoglutethimidum Aminoglutetimid Aminoglutethimide Aminohippurihappo Acidum aminohippuricum Aminohippursyra Aminohippuric acid Aminokapronihappo Acidum aminocaproicum Aminokapronsyra Aminocaproic acid Aminokinuridi Aminoquinuridum Aminokinurid Aminoquinuride Aminolevuliinihappo Acidum aminolevulicum Aminolevulinsyra Aminolevulinic acid Aminonitrotiatsoli Aminonitrothiazolum Aminonitrotiazol Aminonitrothiazole Aminosalisyylihappo Acidum aminosalicylicum Aminosalicylsyra Aminosalisylic acid Aminosalyylikalsium Aminosalylcalcium Aminosalylkalcium Aminosalicylate calcium Aminovaleriaanahappo Acidum aminovalericum Aminovaleriansyra Aminovaleric acid Amiodaroni Amiodaronum Amiodaron Amiodarone Amisulpridi Amisulpridum Amisulprid Amisulpride Amitratsi Amitrazum Amitraz Amitraz Amitriptyliini Amitriptylinum Amitriptylin Amitriptyline Amleksanoksi Amlexanoxum Amlexanox Amlexanox Amlodipiini Amlodipinum Amlodipin Amlodipine Ammoniumkloridi Ammonium chloridum Ammoniumklorid Ammonium Chloride Amobarbitaali Amobarbitalum Amobarbital Amobarbital Amoksapiini Amoxapinum Amoxapin Amoxapine Amoksisilliini Amoxicillinum Amoxicillin Amoxicillin Amorolfiini Amorolfinum Amorolfin Amorolfine Amperotsidihydrokloridi Amperozidi Amperozidhydroklorid Amperozide hydrochloride hydrochloridum Ampisilliini Ampicillinum Ampicillin Ampicillin Amprenaviiri Amprenavirum Amprenavir Amprenavir Amrinoni Amrinonum Amrinon Amrinone Amsakriini Amsacrinum Amsakrin Amsacrine Amyylimetakresoli Amylmetacresolum Amylmetakresol Amylmetacresol Amyylinitriitti Amyli nitris Amylnitrit Amyl nitrite Anagrelidi Anagrelinum Anagrelid Anagrelide Anakinra Anakinrum Anakinra Anakinra Anastrotsoli Anastrozolum Anastrozol Anastrozole Androsta-1,4,6-trieeni-3,17- Androsta-1,4,6-triene-3,17- Androsta-1,4,6-triene-3,17- Androsta-1,4,6-triene-3,17- dioni (ATD) dione (ATD) dione (ATD) dione (ATD) Androstanoloni Androstanolonum Androstanolon Androstanolone Anestesiaeetteri, Aether anaestheticus Narkoseter Ether, anaesthetic narkoosieetteri Angiotensiiniamidi Angiotensinamidum Angiotensinamid Angiotensinamide Anidulafungiini Anidulafunginum Anidulafungin Anidulafungin Anileridiini Anileridinum Anileridin Anileridine Anirasetaami Aniracetamum Aniracetam Aniracetam Anistreplaasi Anistreplasum Anistreplas Anistreplase Ankroni Ancronum Ankron Ancron Ansamysiini Ansamycinum Ansamycin Ansamycin Antatsoliini Antazolinum Antazolin Antazoline Antitrombiini Antithrombinum Antitrombin Antithrombin Apiksabaani Apixabanum Apixaban Apixaban Apomorfiini Apomorphinum Apomorfin Apomorphine Apomorfiinihydrokloridi Apomorphini Apomorfinhydroklorid Apomorphine hydrochloride hydrochloridum Apraklonidiini Apraclonidinum Apraklonidin Apraclonidine Päätös 19.3.2019 LÄÄKELUETTELON AINEET, LIITE 1. 4 ÄMNENA I LÄKEMEDELSFOÖRTECKNINGEN, BILAGA 1. Apramysiinisulfaatti Apramycini sulfas Apramycinsulfat Apramycin sulfate Apremilasti Apremilastum Apremilast Apremilast Aprepitantti Aprepitantum Aprepitant Aprepitant Aprindiini Aprindinum Aprindin Aprindine Aprobarbitaali Aprobarbitalum Aprobarbital Aprobarbital Apronaali Apronalum Apronal Apronal Aprotiniini Aprotininum Aprotinin Aprotinin Arekoliinihydrobromidi Arecolini hydrobromidum Arekolinhydrobromid Arecoline hydrobromide Argatrobaani Argatrobanum Argatropan Argatroban Argipressiini Argipressinum Argipressin Argipressin Arimistaani Arimistanum Arimistane Arimistane Aripipratsoli Aripiprazolum Aripiprazol Aripiprazole Arseenitrioksidi Arseni trioxydum Arseniktrioxid Arsenic Trioxide Arsitumomabi Arcitumomabum
Load more

Recommended publications
  • Arecoline Promotes Migration of A549 Lung Cancer Cells Through Activating the EGFR/Src/FAK Pathway
    toxins Article Arecoline Promotes Migration of A549 Lung Cancer Cells through Activating the EGFR/Src/FAK Pathway Chih-Hsiang Chang 1,†, Mei-Chih Chen 2,3,†, Te-Huan Chiu 1 , Yu-Hsuan Li 1, Wan-Chen Yu 1, Wan-Ling Liao 1, Muhammet Oner 1, Chang-Tze Ricky Yu 4, Chun-Chi Wu 5, Tsung-Ying Yang 6, Chieh-Lin Jerry Teng 7, Kun-Yuan Chiu 8, Kun-Chien Chen 6, Hsin-Yi Wang 9, Chia-Herng Yue 10, Chih-Ho Lai 11 , Jer-Tsong Hsieh 12 and Ho Lin 1,13,14,* 1 Department of Life Sciences, National Chung Hsing University, Taichung 40227, Taiwan; [email protected] (C.-H.C.); [email protected] (T.-H.C.); [email protected] (Y.-H.L.); [email protected] (W.-C.Y.); [email protected] (W.-L.L.); [email protected] (M.O.) 2 Medical Center for Exosomes and Mitochondria Related Diseases, China Medical University Hospital, Taichung 40447, Taiwan; [email protected] 3 Department of Nursing, Asia University, Taichung 41345, Taiwan 4 Department of Applied Chemistry, National Chi Nan University, Nantou 54561, Taiwan; [email protected] 5 Institute of Medicine, Chung Shan Medical University, Taichung 40201, Taiwan; [email protected] 6 Division of Chest Medicine, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] (T.-Y.Y.); [email protected] (K.-C.C.) 7 Division of Hematology/Medical Oncology, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 8 Division of Urology, Taichung Veterans General Hospital, Taichung 40705, Taiwan; [email protected] 9 Department of Nuclear Medicine, Taichung
    [Show full text]
  • Upregulation of Peroxisome Proliferator-Activated Receptor-Α And
    Upregulation of peroxisome proliferator-activated receptor-α and the lipid metabolism pathway promotes carcinogenesis of ampullary cancer Chih-Yang Wang, Ying-Jui Chao, Yi-Ling Chen, Tzu-Wen Wang, Nam Nhut Phan, Hui-Ping Hsu, Yan-Shen Shan, Ming-Derg Lai 1 Supplementary Table 1. Demographics and clinical outcomes of five patients with ampullary cancer Time of Tumor Time to Age Differentia survival/ Sex Staging size Morphology Recurrence recurrence Condition (years) tion expired (cm) (months) (months) T2N0, 51 F 211 Polypoid Unknown No -- Survived 193 stage Ib T2N0, 2.41.5 58 F Mixed Good Yes 14 Expired 17 stage Ib 0.6 T3N0, 4.53.5 68 M Polypoid Good No -- Survived 162 stage IIA 1.2 T3N0, 66 M 110.8 Ulcerative Good Yes 64 Expired 227 stage IIA T3N0, 60 M 21.81 Mixed Moderate Yes 5.6 Expired 16.7 stage IIA 2 Supplementary Table 2. Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis of an ampullary cancer microarray using the Database for Annotation, Visualization and Integrated Discovery (DAVID). This table contains only pathways with p values that ranged 0.0001~0.05. KEGG Pathway p value Genes Pentose and 1.50E-04 UGT1A6, CRYL1, UGT1A8, AKR1B1, UGT2B11, UGT2A3, glucuronate UGT2B10, UGT2B7, XYLB interconversions Drug metabolism 1.63E-04 CYP3A4, XDH, UGT1A6, CYP3A5, CES2, CYP3A7, UGT1A8, NAT2, UGT2B11, DPYD, UGT2A3, UGT2B10, UGT2B7 Maturity-onset 2.43E-04 HNF1A, HNF4A, SLC2A2, PKLR, NEUROD1, HNF4G, diabetes of the PDX1, NR5A2, NKX2-2 young Starch and sucrose 6.03E-04 GBA3, UGT1A6, G6PC, UGT1A8, ENPP3, MGAM, SI, metabolism
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Analysis of Mutations Leading to Para-Aminosalicylic Acid Resistance in Mycobacterium Tuberculosis
    www.nature.com/scientificreports OPEN Analysis of mutations leading to para-aminosalicylic acid resistance in Mycobacterium tuberculosis Received: 9 April 2019 Bharati Pandey1, Sonam Grover2, Jagdeep Kaur1 & Abhinav Grover3 Accepted: 31 July 2019 Thymidylate synthase A (ThyA) is the key enzyme involved in the folate pathway in Mycobacterium Published: xx xx xxxx tuberculosis. Mutation of key residues of ThyA enzyme which are involved in interaction with substrate 2′-deoxyuridine-5′-monophosphate (dUMP), cofactor 5,10-methylenetetrahydrofolate (MTHF), and catalytic site have caused para-aminosalicylic acid (PAS) resistance in TB patients. Focusing on R127L, L143P, C146R, L172P, A182P, and V261G mutations, including wild-type, we performed long molecular dynamics (MD) simulations in explicit solvent to investigate the molecular principles underlying PAS resistance due to missense mutations. We found that these mutations lead to (i) extensive changes in the dUMP and MTHF binding sites, (ii) weak interaction of ThyA enzyme with dUMP and MTHF by inducing conformational changes in the structure, (iii) loss of the hydrogen bond and other atomic interactions and (iv) enhanced movement of protein atoms indicated by principal component analysis (PCA). In this study, MD simulations framework has provided considerable insight into mutation induced conformational changes in the ThyA enzyme of Mycobacterium. Antimicrobial resistance (AMR) threatens the efective treatment of tuberculosis (TB) caused by the bacteria Mycobacterium tuberculosis (Mtb) and has become a serious threat to global public health1. In 2017, there were reports of 5,58000 new TB cases with resistance to rifampicin (frst line drug), of which 82% have developed multidrug-resistant tuberculosis (MDR-TB)2. AMR has been reported to be one of the top health threats globally, so there is an urgent need to proactively address the problem by identifying new drug targets and understanding the drug resistance mechanism3,4.
    [Show full text]
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report
    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
    [Show full text]
  • NIH Public Access Author Manuscript Neuroscience
    NIH Public Access Author Manuscript Neuroscience. Author manuscript; available in PMC 2016 January 22. NIH-PA Author ManuscriptPublished NIH-PA Author Manuscript in final edited NIH-PA Author Manuscript form as: Neuroscience. 2015 January 22; 0: 775–797. doi:10.1016/j.neuroscience.2014.10.044. Early-life Exposure to the SSRI Paroxetine Exacerbates Depression-like Behavior in Anxiety/Depression-prone rats Matthew E. Glover1, Phyllis C. Pugh1, Nateka L. Jackson1, Joshua L. Cohen1, Andrew D. Fant2, Huda Akil3, and Sarah M. Clinton1,§ 1Department of Psychiatry and Behavioral Neurobiology, University of Alabama-Birmingham, USA 2Division of Chemical Biology and Medicinal Chemistry, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, USA 3Molecular and Behavioral Neuroscience Institute, University of Michigan, USA Abstract Selective serotonin reuptake inhibitor (SSRI) antidepressants are the mainstay treatment for the 10–20% of pregnant and postpartum women who suffer major depression, but the effects of SSRIs on their children’s developing brain and later emotional health are poorly understood. SSRI use during pregnancy can elicit antidepressant withdrawal in newborns and increase toddlers’ anxiety and social avoidance. In rodents, perinatal SSRI exposure increases adult depression- and anxiety- like behavior, although certain individuals are more vulnerable to these effects than others. Our study establishes a rodent model of individual differences in susceptibility to perinatal SSRI exposure, utilizing selectively-bred Low Responder (bLR) and High Responder (bHR) rats that were previously bred for high versus low behavioral response to novelty. Pregnant bHR/bLR females were chronically treated with the SSRI paroxetine (10 mg/kg/day p.o.) to examine its effects on offspring’s emotional behavior and gene expression in the developing brain.
    [Show full text]
  • Effect of the Gaba Derivative Succicard on the Lipid and Carbohydrate Metabolism in the Offspring of Rats with Experimental Preeclampsia in Early and Late Ontogeny
    ОРИГИНАЛЬНАЯ СТАТЬЯ DOI: 10.19163/2307-9266-2020-8-5-325-335 EFFECT OF THE GABA DERIVATIVE SUCCICARD ON THE LIPID AND CARBOHYDRATE METABOLISM IN THE OFFSPRING OF RATS WITH EXPERIMENTAL PREECLAMPSIA IN EARLY AND LATE ONTOGENY E.A. Muzyko1, V.N. Perfilova1, A.A. Nesterova2, K.V. Suvorin1, I.N. Tyurenkov1 1 Volgograd State Medical University 1, Pavshikh Bortsov Sq., Volgograd, Russia, 400131 2 Pyatigorsk Medical and Pharmaceutical Institute – branch of Volgograd State Medical University 11, Kalinin Ave., Pyatigorsk, Russia, 357532 E-mail: [email protected] Received 02 Jan 2019 Accepted 08 Jul 2020 Maternal preeclampsia can bring about metabolic disorders in the offspring at different stages of ontogeny. Up to date, no ways of preventive pharmacological correction of lipid and carbohydrate metabolism disorders developing in different peri- ods of ontogeny in the children born to mothers with this pregnancy complication, have been developed. The aim of the experiment was to study the effect of the gamma-aminobutyric acid derivative succicard (22 mg/kg) and its reference drug pantogam (50 mg) administered per os in the course of treatment in puberty (from 40 to 70 days after birth), on the parameters of lipid and carbohydrate metabolism in the offspring of the rats with experimental preeclampsia, in dif- ferent periods of ontogeny. Materials and methods. To assess the activity of lipid and carbohydrate metabolism in the offspring, an oral glucose toler- ance test was performed at 40 days, 3, 6, 12 and 18 months of age. The level of glycosylated hemoglobin was measured at the age of 6, 12, and 18 months, and the concentrations of total cholesterol, high-density lipoprotein cholesterol and tri- glycerides were tested at 40 days, 3, 6, 12, and 18 months of age.
    [Show full text]
  • Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020
    First independent framework for assessing pharmaceutical company action Antimicrobial Resistance Benchmark 2020 Antimicrobial Resistance Benchmark 2020 ACKNOWLEDGEMENTS The Access to Medicine Foundation would like to thank the following people and organisations for their contributions to this report.1 FUNDERS The Antimicrobial Resistance Benchmark research programme is made possible with financial support from UK AID and the Dutch Ministry of Health, Welfare and Sport. Expert Review Committee Research Team Reviewers Hans Hogerzeil - Chair Gabrielle Breugelmans Christine Årdal Gregory Frank Fatema Rafiqi Karen Gallant Nina Grundmann Adrián Alonso Ruiz Hans Hogerzeil Magdalena Kettis Ruth Baron Hitesh Hurkchand Joakim Larsson Dulce Calçada Joakim Larsson Marc Mendelson Moska Hellamand Marc Mendelson Margareth Ndomondo-Sigonda Kevin Outterson Katarina Nedog Sarah Paulin (Observer) Editorial Team Andrew Singer Anna Massey Deirdre Cogan ACCESS TO MEDICINE FOUNDATION Rachel Jones The Access to Medicine Foundation is an independent Emma Ross non-profit organisation based in the Netherlands. It aims to advance access to medicine in low- and middle-income Additional contributors countries by stimulating and guiding the pharmaceutical Thomas Collin-Lefebvre industry to play a greater role in improving access to Alex Kong medicine. Nestor Papanikolaou Address Contact Naritaweg 227-A For more information about this publication, please contact 1043 CB, Amsterdam Jayasree K. Iyer, Executive Director The Netherlands [email protected] +31 (0) 20 215 35 35 www.amrbenchmark.org 1 This acknowledgement is not intended to imply that the individuals and institutions referred to above endorse About the cover: Young woman from the Antimicrobial Resistance Benchmark methodology, Brazil, where 40%-60% of infections are analyses or results.
    [Show full text]
  • EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011)
    EUROPEAN COMMISSION Brussels, 11.7.2011 SEC(2011) 912 final COMMISSION STAFF WORKING PAPER on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances Accompanying the document REPORT FROM THE COMMISSION on the assessment of the functioning of Council Decision 2005/387/JHA on the information exchange, risk assessment and control of new psychoactive substances {COM(2011) 430 final} EN EN TABLE OF CONTENTS 1. Introduction...................................................................................................................3 2. Methodology.................................................................................................................4 3. Key findings from the 2002 evaluation of the Joint Action on synthetic drugs ...........5 4. Overview of notifications, types of substances and trends at EU level 2005-2010......7 5. Other EU legislation relevant for the regulation of new psychoactive substances.....12 6. Functioning of the Council Decision on new psychoactive substances .....................16 7. Findings of the survey among Member States............................................................17 7.1. Assessment of the Council Decision ..........................................................................17 7.2. Stages in the functioning of the Council Decision .....................................................18 7.3. National responses to new psychoactive substances ..................................................20
    [Show full text]
  • Updated WHO MDR-TB Treatment Guidelines and the Use of New Drugs in Children
    Updated WHO MDR-TB treatment guidelines and the use of new drugs in children Annual meeting of the Childhood TB subgroup Liverpool, UK, 26 October 2016 Dr Malgosia Grzemska WHO/HQ, Global TB Programme Outline • Latest epidemiological data • Existing guidelines • 2016 update of the DR-TB treatment guidelines • New recommendations for treatment of RR-TB and MDR- TB in children • Delamanid guideline for use in children and adolescents • Research gaps • Conclusions The Global Burden of TB - 2015 Estimated number Estimated number of cases of deaths 10,4 million 1.8 million* All forms of TB • 1 million Children (10%) • 210,000 children (170,000 HIV negative and 40,000 HIV- positive) HIV-associated TB 1.2 million (11%) 390,000 Multidrug-resistant TB 480,000 190,000 +100,000 RR cases Childhood TB: MDRTB estimates Dodd P., Sismanidis B., Seddon J., Lancet Inf Dis, 21 June 2016: Global burden of drug-resistant tuberculosis in children: a mathematical modelling study • It is estimated that over 67 million children are infected with TB and therefore at risk of developing disease in the future; – 5 mln with INH resistance; 2 mln with MDR; 100,000 with XDR • Every year 25,000 children develop MDRTB and 1200 XDR TB MDR-TB in children • MDR-TB in children is mainly the result of transmission of a strain of M. tuberculosis that is MDR from an adult source case , and therefore often not suspected unless a history of contact with an adult pulmonary MDR-TB case is known. • Referral to a specialist is advised for treatment.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen Et Al
    USOO8603526B2 (12) United States Patent (10) Patent No.: US 8,603,526 B2 Tygesen et al. (45) Date of Patent: Dec. 10, 2013 (54) PHARMACEUTICAL COMPOSITIONS 2008. O152595 A1 6/2008 Emigh et al. RESISTANT TO ABUSE 2008. O166407 A1 7/2008 Shalaby et al. 2008/0299.199 A1 12/2008 Bar-Shalom et al. 2008/0311205 A1 12/2008 Habib et al. (75) Inventors: Peter Holm Tygesen, Smoerum (DK); 2009/0022790 A1 1/2009 Flath et al. Jan Martin Oevergaard, Frederikssund 2010/0203129 A1 8/2010 Andersen et al. (DK); Karsten Lindhardt, Haslev (DK); 2010/0204259 A1 8/2010 Tygesen et al. Louise Inoka Lyhne-versen, Gentofte 2010/0239667 A1 9/2010 Hemmingsen et al. (DK); Martin Rex Olsen, Holbaek 2010, O291205 A1 11/2010 Downie et al. (DK); Anne-Mette Haahr, Birkeroed 2011 O159100 A1 6/2011 Andersen et al. (DK); Jacob Aas Hoellund-Jensen, FOREIGN PATENT DOCUMENTS Frederikssund (DK); Pemille Kristine Hoeyrup Hemmingsen, Bagsvaerd DE 20 2006 014131 1, 2007 (DK) EP O435,726 8, 1991 EP O493513 7, 1992 EP O406315 11, 1992 (73) Assignee: Egalet Ltd., London (GB) EP 1213014 6, 2002 WO WO 89,09066 10, 1989 (*) Notice: Subject to any disclaimer, the term of this WO WO91,040 15 4f1991 patent is extended or adjusted under 35 WO WO95/22962 8, 1995 U.S.C. 154(b) by 489 days. WO WO99,51208 10, 1999 WO WOOOf 41704 T 2000 WO WO 03/024426 3, 2003 (21) Appl. No.: 12/701,429 WO WOO3,O24429 3, 2003 WO WOO3,O24430 3, 2003 (22) Filed: Feb.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]